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Abstract
Background: The role of leptin in the course of liver disease due to chronic viral hepatitis (CVH)
remains controversial. Our aims were to investigate the relationship between serum leptin
concentrations and the severity of liver disease in a cohort of subjects with HBeAg negative chronic
hepatitis B (CHB) and C (CHC) and to analyze the effect of body composition, the leptin system
and insulin resistance together with viral factors on virologic response to antiviral treatment.
Methods: We studied 50 (36 men) consecutive patients suffering from biopsy-proven CVH due
to HBV (n = 25) or HCV (n = 25) infection. Thirty-two (17 men) healthy volunteers served as
controls. Levels of serum leptin and insulin were determined by immunoassays at baseline and at
the end of the treatment.
Results: A significant association between serum leptin levels and the stage of hepatic fibrosis was
noted; patients with cirrhosis presented higher serum leptin levels compared to those with lower
fibrosis stage [CHB patients (17436 pg/ml vs 6028.5 pg/ml, p = 0.03), CHC patients (18014 pg/ml
vs 4385 pg/ml, p = 0.05]. An inverse correlation between lower leptin levels and response to
lamivudine monotherapy was noted in patients with CHB; those with a virologic response
presented lower serum leptin levels (5334 vs 13111.5 pg/ml; p-value = 0.003) than non-responders.
In genotype 1 CHC patients, insulin resistance played a significant role in the response to antiviral
therapy.
Conclusion: Our data clearly suggest that cirrhosis due to CHB or CHC is associated with higher
leptin levels. Increased serum leptin levels represent a negative prognostic factor for response to
lamivudine monotherapy in patients with CHB. In CHC patients insulin resistance strongly
influences the response to antiviral treatment in patients infected with genotype 1.
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Background
Leptin is a circulating 16-kDa non-glycosylated protein
secreted from the adipocytes of white fat into the blood
[1]. The levels of leptin are related to the adipose tissue
mass, and signal the central nervous system of the pres-
ence of sufficient energy stores, causing a response charac-
terized by anorexia and increased energy expenditure [2].
Leptin has been also implicated in many actions includ-
ing liver fibrogenesis [3-6]. Serum leptin levels have been
found higher in patients with chronic hepatitis C (CHC)
and particular in those with more severe fibrosis or cirrho-
sis [7]; however the results are conflicting [8-14].
Recent observations in patients with CHC indicate that
liver steatosis and insulin resistance has been associated
with progressive hepatic fibrosis and sustained virologic
response (SVR) to antiviral treatment [15]. It is known
that serum leptin regulates insulin secretion and tissue
responsiveness to this hormone [16]. Nevertheless, the
relationship between leptin and insulin resistance in
patients with chronic viral hepatitis (CVH) seems obscure
at present; both presence [12] and absence [13] of associ-
ation between serum leptin and insulin levels have been
observed in CVH patients.
In view of the obscure role of serum leptin in CVH we
were interested in its role in chronic hepatitis B (CHB)
and CHC infection. To investigate this we measured the
serum leptin levels in 25 patients with HBeAg negative
CHB and 25 patients with CHC before and after antiviral
therapy and matched controls and assessed its relation-
ship to anthropometric, metabolic and histopathological
parameters. The aims of the present study were (a) to
assess the relationship between serum leptin levels and
the stage of liver disease in a cohort of subjects with CHB
and CHC, (b) to evaluate the relationship among leptin,
insulin and the stage of hepatic fibrosis and (c) to evaluate
the effect of body composition, the leptin system and
insulin resistance together with viral factors on SVR in
patients with CVH receiving antiviral therapy.
Methods
2.1 Patients
This prospective open-label study included 50 consecu-
tive patients with hepatitis C virus (HCV) (n = 25) or hep-
atitis B virus (HBV) (n = 25) infection referred to our Liver
Unit between January 2004 and January 2006. All patients
were evaluated with physical examination, laboratory
tests and a baseline liver biopsy. Entry criteria included
patients aged 16–75 year, elevated alanine aminotrans-
ferase (ALT) levels for at least 6 months on at least 3 occa-
sions and HBsAg or anti-HCV and HCV-RNA positivity.
We excluded patients with: (a) Other causes of chronic
liver disease (HBsAg for HCV patients, anti-HCV or detect-
able antibodies against hepatitis delta for HBV patients,
alcoholism, Wilson's disease, drugs, haemochromatosis,
autoimmune hepatitis), (b) Seropositivity for anti-HIV,
(c) Decompensated liver disease, (d) History of heart fail-
ure, diabetes, thyroid diseases, abnormal renal function
and cancer, (e) Morbid obesity i.e. body mass index (BMI)
> 40, (f) Contraindications or previous treatment with
antiviral agents (interferon, nucleos(t)ide analogues),
metformin, vitamin E, or a thiazolidinedione and (g) Use
of drugs known to induce liver steatosis (corticosteroids,
amiodarone, tamoxifen, valproic acid) within the last 6
months. Weight alterations over the previous year were
recorded, and patients with changes more than 10% were
also excluded from the study.
2.2 Controls
The control group comprised 32 (17 men and 15 women)
healthy volunteers (doctors, nurses, students) matched
for BMI from Polykliniki General Hospital and considered
healthy on the basis of history, physical examination and
laboratory tests. None received any medication and had
normal liver enzymes and no clinical, laboratory or imag-
ing evidence of liver disease. Subjects who have had a
restriction of diet for losing weight during the last three
months have not been included into control group. The
study was performed in accordance with the Helsinki Dec-
laration II, with the approval of the Ethics Committee of
Polyclinic General Hospital and all patients and control
subjects gave their verbal informed consent.
2.3 Clinic and Laboratory Evaluation
Clinical and laboratory data were collected on the date
that baseline liver biopsy was performed. A complete
medical history and physical examination was accom-
plished in all patients and controls. Height (cm) and
weight (kg) were determined at baseline to calculate BMI,
as an expression of the overall state of nutrition. The fat
mass index (FMI) was calculated according to the formula
FMI = (BMI-13)/1.33. Blood samples were obtained at
08.00–09.00 h after an overnight fast, stored for one hour
at room temperature, centrifuged and serum was sepa-
rated. Biochemical analyses were performed at the same
day. Concentrations of glucose, ALT, aspartate ami-
notransferase (AST), total bilirubin, albumin, total cho-
lesterol and triglycerides were measured. Commercially
available enzyme immunoassays (EIA) were used for the
detection of HBsAg, HbeAg, anti-HBe, anti-HBc (Roche
Diagnostics GmbH, D-68298 Mannheim). Anti-HCV was
tested by a third-generation EIA (Roche Diagnostics
GmbH, D-68298 Mannheim). Serum HBV DNA concen-
trations were determined by a commercially available
quantitative assay (Amplicor HBV MONITOR assay,
Roche Diagnostics, GmbH Mannheim, Germany). Serum
HCV RNA determination was carried out by the Amplicor
HCV test (Roche Molecular System). HCV genotyping wasBMC Gastroenterology 2007, 7:17 http://www.biomedcentral.com/1471-230X/7/17
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performed by reverse hybridization (InnoLiPA HCV;
Innogenetics, Gent, Belgium).
Insulin was measured using a two-site electrochemilumi-
nescence immunoassay performed on the Roche Elecsus
immunoassay analyzer. Intra-assay C.V.'s were 2.6, 2.8
and 2.5% at 6.36, 20.9,747 µU/mL, respectively.
Serum samples for measurement of leptin were stored at -
80°C until subsequent analysis. The quantitative determi-
nation of human leptin was conducted in serum by solid-
phase ELISA techniques, using commercially available kit,
purchased from R&D Systems Inc., (Minneapolis, USA).
Every sample was run in duplicate, measurements differed
by less than 10%, and the mean value was calculated and
used for statistical analysis. The intra- and inter-assay pre-
cision coefficient of variation (CV %) of leptin ranged
between 3.0–3.3 and 3.5–5.4 % respectively at different
levels. Serum glucose and insulin levels were used to
determine the homeostatic model assessment (HOMA-
IR) described by Matthews et al using the formula IR =
(insulinxglucose)/22.5 [17]. Higher insulin resistance is
indicated by higher values of HOMA-IR. As previously rec-
ommended, insulin resistance was arbitrarily considered
when it was > 2, whereas HOMA-IR values > 4 were con-
sidered as a prediabetic state [18].
2.4 Study Protocol
All HBV patients were treated with orally lamivudine 100
mg daily. HCV patients received 180 µg of peginterferon
alfa-2α weekly, plus ribavirin according to genotype and
body weight [19]. Onset of treatment was not over 2
months after baseline liver biopsy. All patients were fol-
lowed up in the out-patient clinic and had physical exam-
ination and blood drawn for liver chemistry, creatinine,
full blood count prothrombin time, cholesterol and trig-
lyceride at months 1, 2, 3 and then every 3 months for
HBV patients and every month for HCV patients. Serum
HBV DNA and HCV RNA were evaluated at least every 3–
6 months. Serum leptin and insulin were measured at last
visit for HBV patients and 3–6 months after treatment dis-
continuation for HCV patients.
Virological response was considered as the clearance of
serum HBV DNA by polymerase chain reaction (PCR)
assay and biochemical response as the decline of transam-
inase levels within normal range. Virological break-
through was considered as the reappearance of detectable
serum HBV DNA by PCR after initial response. For
patients with chronic HCV infection SVR was considered
when HCV RNA was not detected by qualitative PCR 6
months after treatment discontinuation.
2.5 Histological Assessment
All patients underwent baseline liver biopsy; 36 under-
went a follow-up liver biopsy (23 with CHB at the end of
the 1st year of treatment and 13 with CHC at or about the
end of treatment). Liver biopsies were evaluated by expe-
rienced pathologists who were unaware of the clinical and
virological status of patients. The histologic lesions were
analyzed according to Ishak classification system [20].
Steatosis was assessed as the percentage of hepatocytes
containing macrovesicular fat droplets. It was graded as
follows: 0 = no steatosis; 1 = mild: < 33% of hepatocytes
affected; 2 = moderate: 33% to 66% of hepatocytes
affected; 3 = severe: > 66% of hepatocytes affected [21].
2.6 Statistical Analysis
Analyses were performed using STATA 8.0 statistical pack-
age (Stata Corporation, College Station, TX, U.S.A.). The
clinical, biochemical, and virologic data are presented as
median with range as most data did not show a Gaussian
distribution. Serum HBV DNA and HCV RNA concentra-
tions below detection limit (< 400 copies/mL and 50IU/l
or 260 copies/mL respectively) were imputed to 399 cop-
ies/mL and 259 copies/mL respectively for the analyses.
All HBV DNA and HCV RNA values were log-transformed
for normality. Continuous variables were compared using
the Wilcoxon's rank-sum and Mann-Whitney tests. Cate-
gorical variables were compared using χ2 or Fisher's exact
tests as appropriate. Spearman's correlation coefficients
were calculated for estimation of the level of association
between two variables. A multiple regression analysis was
performed with leptin as the dependent variable and age,
gender, BMI, FMI, histological and biochemical data as
independent variables. Two-sided p-values less than 0.05
were considered statistically significant.
Results
3.1 Characteristics of the patient and control population
Due to the gender dependency of serum leptin levels,
patients and controls were divided in two groups (men
and women-Table 1). All patients with HBV infection
were HBeAg (-), anti HBeAg (+) and the median serum
HBV DNA concentrations were 784000 cp/mL (770–
192000000). The median serum HCV RNA concentra-
tions were 769000 cp/mL (400, 2452635). Genotype dis-
tribution in patients with HCV hepatitis was as follows: 11
patients (44%) were infected with genotype 1, 9 (36%)
with genotype 3 and 5 (20%) with genotype 4. Anthropo-
metric, metabolic and histological parameters were simi-
lar in CHB and in CHC patients.
Table 2 summarizes the liver histology findings. Severe
steatosis was observed only in one CHC patient. The per-
centage of steatosis was not different between CHB and
CHC group (p = 0.5) and between cirrhotics and non-cir-
rhotics (p = 0.7).BMC Gastroenterology 2007, 7:17 http://www.biomedcentral.com/1471-230X/7/17
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Table 1: 
A
Baseline characteristics for men. Data are reported as median and range
Chronic viral hepatitis patients (n = 36) Control Subjects (n = 17)
Age (years) 45.5 (19,73) 62.5 (21,79)
Height (cm) 173 (160,190) 173 (167,186)
Weight (kg) 81.5 (58,118) 75 (62,100)
BMI (kg/m2) 26.3 (20.3,36.2) 25.1 (21.5, 29.5)
FMI 9.99 (5.5, 17.4) 9.09 (6.39, 12.4)
Glucose (mg/dl) 96.5 (70,147)* 88 (60,183)
Insulin (µU/mL) 7.34 (0.73, 125.8) 9.18 (3.05,17.28)
HOMA-IR 2 (0.12–7.36) 2 (0.88–4.89)
AST (IU/l) 59 (19,274)* 26 (21,35)
ALT (IU/l) 105 (24,366)* 25 (20,36)
Leptin (pg/ml) 5134 (695,30430) 5054 (588,15325)
B
Baseline characteristics for women. Data are reported as median and range
Chronic viral hepatitis patients (n = 14) Control Subjects (n = 15)
Age (years) 38 (16,70) 51 (20,74)
Height (cm) 165 (156,169) 160 (153,168)
Weight (kg) 77 (51,112) 74 (60,94)
BMI (kg/m2) 29.7 (18,39.3) 29.5 (23.1,38.8)
FMI 12.6 (3.81,19.7) 12.4 (7.59,17.39)
Glucose (mg/dl) 80.5 (70,175) 81 (60,156)
Insulin (µU/mL) 5.65 (0.73,16.47) 8.43 (5.67,67.76)
HOMA-IR 1.02 (0.12, 6.25) 1.53 (0.95–13.5)
AST (IU/l) 55 (38,129)* 27 (20,35)
ALT (IU/l) 66 (54,269)* 27 (21,32)
Leptin (pg/ml) 11372(1714,43605) 18990(4876,48928)
*p < 0.05 vs controls
Table 2: Histological characteristics of the patient population
Hepatitis B patients Hepatitis C patients
Liver biopsy features Baseline liver biopsy Liver Biopsy after treatment Baseline liver biopsy Liver Biopsy after treatment
HAI*1 8(3,13)*1 4 (0,12)*1 7 (2,14)*1 4 (0,9)*1
0–8 N(%) 11(44) 18 (78.26) 16 (64) 10 (77)
9–12 N(%) 13 (52) 5 (21.74) 8 (32) 3 (23)
>  1 2  N ( % ) 1  ( 4 )01  ( 4 )0
Fibrosis 4 (1,6) 2 (0,6) 3 (1,6) 2 (0,6)
Cirrhosis N(%)*2 9 (36) 5 (21.74) 5 (20) 3 (23)
Steatosis*3 0(0,1) 4 (0,12) 0 (0,3) 0 (0,1)
No steatosis N(%) 16(64) 19 (82.61) 13 (54.17) 12 (92.3)
Mild N(%) 9 (36) 4 (17.39) 10 (41.67) 1(7.69)
Moderate N (%) 0 0 0 0
Severe N (%) 0 0 1 (4.17) 0
*1Histological activity (HAI), fibrosis and steatosis data ere expressed as median (range).
*2 Cirrhosis: Stage of fibrosis 5&6 (Ishak classification system)
*3 Steatosis: Mild: < 33% of hepatocytes affected; Moderate: 33% to 66% of hepatocytes affected; Severe: > 66% of hepatocytes affected.BMC Gastroenterology 2007, 7:17 http://www.biomedcentral.com/1471-230X/7/17
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3.2 Relationship between serum leptin and insulin levels 
and clinical, biochemical and histological data of patients 
and controls
Serum leptin levels were significantly higher in females
than in males in CHB (p = 0.05), CHC (p = 0.05), cirrhotic
patients' group (p = 0.04) and also the control group (p <
0.001).
Non-cirrhotic female patients both in CHB and CHC
patients' group presented significantly lower serum leptin
levels than controls (p = 0.01). Patients with CHB and def-
inite histological diagnosis of cirrhosis (stage 6) at base-
line liver biopsy had significantly higher levels of leptin
compared to those with lower fibrosis stage (17436 pg/
mL vs 6028.5 pg/mL, p = 0.03). Similar results were
observed when the CHC group of patients was analyzed
(18014 pg/mL vs 4385 pg/mL, p = 0.05)
In HBV patients significant positive correlations were
observed between serum leptin levels and weight (r =
0.65, p = 0.001), BMI and FMI (r = 0.82, p < 0.0001), and
in HCV patients between serum leptin levels and age (r =
0.56, p = 0.003) and stage of fibrosis (r = 0.47, p = 0.01).
The correlation between serum leptin levels and BMI in
healthy subjects was similar to that noted in the patients'
group (r = 0.67, p = 0.001).
Significant associations between serum leptin and insulin
levels (r = 0.69, p = 0.02) and serum leptin and HOMA-IR
(r = 0.61, p = 0.06) were noted in CHC patients infected
with genotype 1. Serum insulin levels and HOMA-IR were
higher (10.33 vs 5.48 µU/mL, p = 0.03 and 3.02 vs 1.3, p
= 0.01 respectively) in HCV patients infected with geno-
type 1 in comparison with other genotypes, whereas no
difference was seen in BMI or leptin levels with respect to
genotypes.
A multiple regression analysis, in which the dependent
variable was serum leptin levels and independent varia-
bles were gender, age, BMI, liver fibrosis and steatosis,
transaminase levels, insulin, HOMA-IR and categorized
individuals according to their conditions (patients and
controls), was performed showing that leptin concentra-
tion was jointly significantly correlated with gender, BMI
and stage of fibrosis at the baseline liver biopsy in patients
with CHB (R2 = 0.6, p = 0.004) and in CHC patients (R2 =
0.72, p = 0.004) .
Age was the only variable significantly associated with cir-
rhosis; each 10-year increase in age was associated with a
1.7 (95% CI: 1.01–1.14, p = 0.05) fold increase in preva-
lence of cirrhosis in CHB patients. The same trend [1.7
fold increase in prevalence of cirrhosis with each decade
increase in age (95% CI: 0.99–1.15, p = 0.07)] was also
observed in CHC patients but statistical significance was
not reached.
3.3 Factors associated with virologic response to antiviral 
treatment
We did not observe any significant change of BMI in
patients' group (before, at 12 weeks of, and at the end of
therapy (26.3, 28.1, 27.8 kg/m2  respectively). Overall
(both HCV and HBV patients), 30 of 50 patients (60%)
fulfilled our criteria for response (transaminase levels
within normal ranges and nondetectable HBV DNA or
HCV RNA by PCR). In multivariate logistic regression
analysis the only factor negatively associated with
response was serum leptin levels. Responders presented
significantly lower baseline serum leptin levels than non-
responders (4642.5 vs 10733 pg/mL; p-value = 0.002-
Table 3).
Our subgroup analysis for HBV patients showed that
among the 25 CHB patients, 19 of 25 (76%) experienced
an on treatment virologic response after a median of 18.5
months duration of follow-up. Patients with CHB who
responded to antiviral treatment had lower serum leptin
levels (5334 vs 13111.5 pg/mL; p-value = 0.003) than
non-responders. When corrected by gender, the relation-
ship between leptin concentration and lamivudine
response was more obvious in the subgroup of male
patients with CHB; responders to lamivudine treatment
had lower serum leptin levels (4980 vs 13078 pg/mL; p-
value = 0.01) than non-responders.
Table 3: Baseline characteristics associated with response to antiviral treatment after multivariate logistic regression analysis a) of the 
whole cohort of patients b) of CHB patients c) of CHC patients (only variables with statistical significance are shown). Data are 
reported as median and range.
Total number of responders (n = 30) Total number of non-responders (n = 20) p-value
Leptin (pg/ml) 4642.5 (917, 32879)* 10733 (695, 43605) 0.002
CHB patients Responders to lamivudine monotherapy (n = 19) Non-responders to lamivudine monotherapy 
(n = 6)
p-value
Leptin (pg/ml) 5334 (917, 17436) 13111.5 (8844,43605) 0.003
CHC patients Sustained responders (n = 11) Nonsustained responders (n = 14) p-value
Genotype 3 7 (63.6%) 4/14 (28%) 0.01BMC Gastroenterology 2007, 7:17 http://www.biomedcentral.com/1471-230X/7/17
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Twenty four of the 25 CHC patients completed full treat-
ment course; one patient discontinued due to severe
fatigue and anemia at the 3rd month of treatment. SVR was
achieved in 11 of 25 (44%) CHC patients; those CHC
patients with baseline HCV RNA higher than 800000 cp/
mL were 7.69 (95% CI: 1.08–50, p = 0.04) times less likely
to present SVR. After multivariate logistic regression anal-
ysis, genotype was the only significant variable associated
with SVR; patients infected with genotype 3 were 10.5
(95% CI: 1.5–72.8, p = 0.01) times more likely to present
sustained virologic response than non-genotype 3 CHC
patients. Subgroup analysis according to genotype has
shown that insulin resistance strongly influenced the
response only in patients infected with genotype 1 (Figure
1). The rate of SVR was 14% (1/7 patients) in insulin-
resistant patients (HOMA-IR > 2), compared 100% (3/3
patients) in patients with HOMA-IR < 2 (χ2 = 0, 01). The
SVR rate in genotype 1 patients segregated with respect to
HOMA-IR was 100% (3/3 patients) if HOMA-IR < 2, 25%
(1/4 patients) if HOMA-IR was between 2 and 4, and 0%
(0/3 patients) if HOMA-IR was > 4 (p = 0.04).
Discussion
The results of this study further confirm that in patients
with CVH the physiological correlation among serum lep-
tin level, gender and BMI was well preserved [11,22,23].
In addition, our data have shown that serum leptin levels
in patients with HBeAg negative CHB and CHC are asso-
ciated with severe fibrosis and response to antiviral treat-
ment.
The behavior of leptin concentrations in the course of
liver disease due to HBV and HCV infection is still under
investigation. Several studies have shown no association
between serum leptin and fibrosis in CHB or CHC
[4,12,13,24,25]. In contrast to these studies we and others
[8,9,26] have shown that serum leptin levels are inde-
pendently associated with severe fibrosis in patients with
CVH. The reason for this discrepancy is not clear. Perhaps
the different selection criteria and the different form of
chronic infection may explain our results.
The mechanisms involved in the increase of leptin accord-
ing to the stage of hepatic fibrosis are obscure. The modi-
fied stellate cells may express leptin, the cirrhotic liver
could be expected to produce leptin and contribute to the
rise in circulating leptin with a significant hepatic venous
spillover [3]. A cytokine-leptin link hypothesis has also
been suggested as a contributing factor to cirrhotic hyper-
leptinemia; presumably activated tumor necrosis factor-α
(TNF-α) in cirrhosis can cause excessive release of leptin
from adipose tissue [26]. Henriksen et al. suggested that
the elevated circulating leptin in patients with alcoholic
cirrhosis was most likely caused by a combination of
decreased renal extraction and increased release from sub-
cutaneous abdominal, femoral, gluteal, retroperitoneal,
pelvic and upper limb fat tissue areas [27].
Another important finding of our study is that in patients
with chronic viral hepatitis, high baseline serum leptin
levels represent a negative prognostic factor for response
to antiviral therapy. Our subgroup analysis according to
viral etiologic factor showed that the above finding was
more obvious for male HBV patients. After performing
multivariate analysis of several factors low leptin levels
were the only feature associated with favorable response
to lamivudine monotherapy. It is known that leptin has
proinflammatory properties in vitro, primarily by upregu-
lating the production of several important proinflamma-
tory Th1 cytokines-including interleukin (IL)-1, IL-6, IL-
12 and TNF-α and decreasing the production of the anti-
inflammatory cytokine IL-10 [28]. Given the known regu-
latory effects of these cytokines [29], it thus appears that
leptin may help to amplify selected proinflammatory
responses; there is evidence that the effects of lamivudine
treatment depend on patient's pre-existing active immune
response against HBV [30]. It should be noted that our
subgroup analysis for CHC patients did not reveal a signif-
icant association between serum leptin levels and the
response to antiviral therapy. Possible explanations could
be the different role of cytokines and immune response in
HCV infection and the relatively small number of patients
in CHC group; recently Eguchi et al. reported a significant
association between high serum leptin level and IFN
resistance in a subgroup of 50 patients with low viral load
(< 100 MU/L) [31].
Senescence is associated with a progressive increase in
insulin resistance [32]. In our study, however, we did not
Distribution of homeostasis model assessment for insulin  resistance (HOMA-IR) according to sustained virologic  response in genotype 1 and non genotype 1 infected CHC  patients Figure 1
Distribution of homeostasis model assessment for insulin 
resistance (HOMA-IR) according to sustained virologic 
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find a significant difference in insulin resistance between
patients and controls although the latter group was with
higher median age; a reasonable explanation might be the
involvement of CVH in the development of insulin resist-
ance, a view that has been also supported by previous
reports [33,34].
Recent evidence suggests that insulin resistance is associ-
ated with severe fibrosis and poor response to treatment
in patients with CHC [35-39]. In our study we determined
for first time the insulin resistance in a sizeable cohort of
CHB and CHC patients as one could hypothesize an inter-
action between insulin resistance and leptin regarding
their actions in liver fibrogenesis. We did not observe any
association in the total group of our patients. However
our subgroup analysis has clearly shown an association
between insulin resistance and virologic response in
patients infected with genotype 1. Our study provides also
further evidence that insulin resistance impairs sustained
response to antiviral treatment in genotype 1 infected
patients and as already proposed by Romero-Gomez et al,
HOMA-IR could represent the best host marker to predict
SVR in genotype 1 infected patients [38]. Therefore
although the number of studies and included patients are
small, our data suggest that therapeutic interventions
aimed at decreasing insulin resistance in genotype-1
infected patients are necessary in order to increase
response rates in these difficult to treat patients.
Conclusion
Higher leptin levels are associated with severe levels of
fibrosis in patients with CVH and represent a negative
prognostic factor for virologic response to lamivudine
monotherapy in patients with HBeAg negative CHB.
Therefore in the forthcoming era of new nucleos(t)ide
analogues further clinical research is necessary in order to
explore the importance of serum leptin levels in this resist-
ant to conventional antiviral treatment group of patients.
On the other hand our data suggest that treatment strate-
gies focusing on improvement of underlying metabolic
factors seem appropriate in patients infected with HCV
genotype 1.
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